Rosiglitazone

Generic Name: Rosiglitazone

Brand Names: Avandamet, Avandia

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₃O_₃S

CAS Number: 122320-73-4

Unique Ingredient Identifier: 05V02F2KDG

Background: Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.

Indication: Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

Phase 4

Completed

Conditions: Hepatitis C

Interventions: Drug: rosiglitazone

First Posted Date: 2005-09-21

Last Posted Date: 2012-02-14

Lead Sponsor: Brooke Army Medical Center

Target Recruit Count: 34

Registration Number: NCT00207402

Locations: 🇺🇸
Brooke Army Medical Center, Ft. Sam Houston, Texas, United States

Study In Patients With Insulin Resistance

Phase 3

Completed

Conditions: Insulin Resistance

First Posted Date: 2005-09-20

Last Posted Date: 2016-12-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT00197132

Locations: 🇳🇱
GSK Clinical Trials Call Center, Nijmegen, Netherlands

Preferred Treatment of Type 1.5 Diabetes

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: glyburide
Drug: rosiglitazone

First Posted Date: 2005-09-19

Last Posted Date: 2018-03-29

Lead Sponsor: University of Washington

Target Recruit Count: 64

Registration Number: NCT00194896

Locations: 🇺🇸
DVA Puget Sound Health Care System, Seattle, Washington, United States

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Phase 3

Completed

Conditions: Adenocarcinoma of the Prostate
Prostate Cancer

Interventions: Other: Placebo
Drug: Rosiglitazone

First Posted Date: 2005-09-16

Last Posted Date: 2013-05-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 100

Registration Number: NCT00182052

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States